Have a feature idea you'd love to see implemented?
Let us know!
RGLS Regulus Therapeutics Inc
Price (delayed)
$1.59
Market cap
$104.15M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.06
Enterprise value
$78.19M
Regulus Therapeutics Inc. is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop
Highlights
RGLS's debt has dropped by 86% year-on-year and by 29% since the previous quarter
RGLS's EPS is up by 33% year-on-year and by 15% since the previous quarter
Regulus Therapeutics's net income has decreased by 45% YoY and by 18% from the previous quarter
Regulus Therapeutics's quick ratio has decreased by 25% from the previous quarter
Key stats
What are the main financial stats of RGLS
Market
Valuations
Earnings
Shares outstanding
65.5M
Market cap
$104.15M
Enterprise value
$78.19M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.2
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Net income
-$41.63M
EBIT
-$41.37M
EBITDA
-$41.03M
Free cash flow
-$36.36M
Per share
Balance sheet
Liquidity
EPS
-$1.06
EPS diluted
-$1.06
Free cash flow per share
-$0.56
Book value per share
$1.33
Revenue per share
$0
TBVPS
$1.43
Total assets
$93.76M
Total liabilities
$6.96M
Debt
$476,000
Equity
$86.81M
Working capital
$85.21M
Debt to equity
0.01
Current ratio
14.14
Quick ratio
13.48
Net debt/EBITDA
0.63
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-48.6%
Return on equity
-53.1%
Return on invested capital
-73.7%
Return on capital employed
-47.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RGLS stock price
How has the Regulus Therapeutics stock price performed over time
Intraday
2.58%
1 week
0.63%
1 month
13.57%
1 year
20.45%
YTD
24.22%
QTD
1.27%
Financial performance
How have Regulus Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$44.6M
Net income
-$41.63M
Gross margin
N/A
Net margin
N/A
The operating income has declined by 50% year-on-year and by 19% since the previous quarter
Regulus Therapeutics's net income has decreased by 45% YoY and by 18% from the previous quarter
Growth
What is Regulus Therapeutics's growth rate over time
Valuation
What is Regulus Therapeutics stock price valuation
P/E
N/A
P/B
1.2
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
RGLS's EPS is up by 33% year-on-year and by 15% since the previous quarter
The stock's price to book (P/B) is 14% less than its 5-year quarterly average of 1.4 and 8% less than its last 4 quarters average of 1.3
Regulus Therapeutics's equity has decreased by 12% from the previous quarter
Efficiency
How efficient is Regulus Therapeutics business performance
The ROIC has soared by 81% YoY and by 10% from the previous quarter
Regulus Therapeutics's return on equity has increased by 44% YoY and by 4.3% QoQ
RGLS's return on assets is up by 30% year-on-year
Dividends
What is RGLS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RGLS.
Financial health
How did Regulus Therapeutics financials performed over time
Regulus Therapeutics's total assets has surged by 148% YoY but it has decreased by 10% QoQ
RGLS's total liabilities is down by 27% YoY but it is up by 17% QoQ
RGLS's debt is 99% smaller than its equity
The debt to equity has plunged by 92% YoY
RGLS's debt has dropped by 86% year-on-year and by 29% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.